Reuters - U.S. officials deferred ruling on
over-the-counter sales of Barr Pharmaceuticals Inc.'s
"morning-after" contraceptive on Friday, sparking charges that
repeated delays were motivated by politics rather than science.{br}{br}View the Entire Article{br}{br}Click Here to Launch in a new Window